Mechanism of Action.
FOX04-DRI is a D-retro-inverso peptide designed to interfere with the interaction between the transcription factor FOXO4 and the tumor suppressor p53 in senescent cells. Cellular senescence is a state where damaged cells permanently stop dividing but resist apoptosis, accumulating with age and secreting inflammatory factors (SASP - senescence-associated secretory phenotype). In senescent cells, FOXO4 binds p53 in the nucleus, preventing p53 from triggering apoptosis. FOX04-DRI competitively displaces p53 from FOXO4, freeing p53 to activate its pro-apoptotic program. Crucially, this interaction is specific to senescent cells; healthy cells have low FOXO4 nuclear expression, so FOX04-DRI does not trigger apoptosis in normal tissue. The D-retro-inverso modification uses D-amino acids in reverse sequence, making the peptide resistant to proteolytic degradation.
Research Summary.
The foundational study by Baar et al. (2017) in Cell demonstrated that FOX04-DRI selectively killed senescent cells in culture and in naturally aged mice. Treated aged mice showed restored fitness, fur density, and renal function. Fast-aged (XpdTTD/TTD) mice showed similar rejuvenation effects. The concept of targeted senescent cell clearance (senolytics) has become one of the most active areas of gerontology research. However, FOX04-DRI remains early in development compared to small-molecule senolytics like dasatinib+quercetin. Limited independent replication of the original findings has been published, and no human clinical trials have been conducted. The peptide nature of FOX04-DRI creates manufacturing and delivery challenges compared to small molecules.
Side Effects & Safety.
Safety data for FOX04-DRI is limited to preclinical studies. In the original mouse studies, transient weight loss was observed following treatment, likely from diarrhea associated with clearance of senescent cells from intestinal tissue. No serious organ toxicity was reported. Theoretical concerns include off-target effects if the FOXO4-p53 interaction is disrupted in non-senescent cells, potential immune reactions from rapid clearance of senescent cells and SASP release, and unknown long-term effects of senescent cell depletion on tissue homeostasis. As an early-stage investigational compound with no human data, comprehensive safety assessment is not available.
Legal Status & Access.
FOX04-DRI is an investigational research compound. It has not entered clinical trials and is not FDA-approved. Available from a small number of research peptide suppliers. Its novel mechanism and limited production sources make quality verification particularly important.